从药物计量学视角看抗菌药物剂量个体化:现状全景
本文综述了抗菌药物剂量个体化的当前策略,包括治疗药物监测(TDM)结合群体药代动力学(popPK)模型实现模型引导的精准给药(MIPD),以及机器学习技术的整合潜力。文章还讨论了模型选择与验证、暴露-效应关系理解、模型复杂度与临床可用性平衡、监管合规及软件实施等挑战,并展望了实时生物传感器等新兴技术对TDM的革新前景。
要点
- TDM结合popPK模型可实现MIPD,优化抗菌药物个体化给药。
- 机器学习有望通过挖掘大数据复杂模式增强剂量个体化。
- 实施MIPD需关注模型选择验证、暴露-效应关系及临床可用性平衡。
核心结论
- TDM、先进建模技术与机器学习在数字健康领域的持续整合,有望提升抗菌药物治疗的个体化水平。
研究设计与样本
- 本文为综述,围绕药物计量学视角下抗菌药物剂量个体化的当前格局进行论述。
主要发现
- TDM结合popPK模型可实施MIPD,popPK模型能数学描述药物在群体中的行为并结合患者TDM数据优化给药方案。
- 机器学习技术有望通过识别大数据集中的复杂模式进一步增强剂量个体化。
- 实时生物传感器等新兴技术可能通过连续监测、即时频繁剂量调整和近患者检测革新TDM。
临床怎么用
- 临床可应用TDM数据结合popPK模型进行模型引导的精准给药,以优化抗菌药物个体化治疗方案。
- 实施剂量个体化时需严格进行模型选择与验证,确保适用于目标人群,并平衡模型复杂度与临床可用性。
- 需理解药物暴露与临床结局的关系,并关注监管合规、结局测量及软件实施等实际问题。
局限性
- 实施上述方法面临模型选择与验证的严谨性挑战,需确保模型适用于目标人群。
- 需在模型复杂度与临床可用性之间取得平衡,并考虑监管合规与软件实施等实际因素。
- 应用技术时需重视模型开发、验证及伦理考量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Successful antimicrobial therapy depends on achieving optimal drug concentrations within individual patients. Inter-patient variability in pharmacokinetics (PK) and differences in pathogen susceptibility (reflected in the minimum inhibitory concentration, [MIC]) necessitate personalised approaches. Dose individualisation strategies aim to address this challenge, improving treatment outcomes and minimising the risk of toxicity and antimicrobial resistance. Therapeutic drug monitoring (TDM), with the application of population pharmacokinetic (popPK) models, enables model-informed precision dosing (MIPD). PopPK models mathematically describe drug behaviour across populations and can be combined with patient-specific TDM data to optimise dosing regimens. The integration of machine learning (ML) techniques promises to further enhance dose individualisation by identifying complex patterns within extensive datasets. Implementing these approaches involves challenges, including rigorous model selection and validation to ensure suitability for target populations. Understanding the relationship between drug exposure and clinical outcomes is crucial, as is striking a balance between model complexity and clinical usability. Additionally, regulatory compliance, outcome measurement, and practical considerations for software implementation will be addressed. Emerging technologies, such as real-time biosensors, hold the potential for revolutionising TDM by enabling continuous monitoring, immediate and frequent dose adjustments, and near patient testing. The ongoing integration of TDM, advanced modelling techniques, and ML within the evolving digital health care landscape offers a potential for enhancing antimicrobial therapy. Careful attention to model development, validation, and ethical considerations of the applied techniques is paramount for successfully optimising antimicrobial treatment for the individual patient.
引用
- Preijers T, Muller AE, Abdulla A, et al. Dose Individualisation of Antimicrobials from a Pharmacometric Standpoint: The Current Landscape. Drugs. 2024. PMID: 39240531. doi:10.1007/s40265-024-02084-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。